Asset
ELUFORSEN
ProQR Therapeutics N.V. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02532764 | phase1_2 | completed | 2015-06-01 | 2017-09-14 | ProQR Therapeutics | Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients |
| NCT02564354 | phase1 | completed | 2015-09-01 | 2016-09-01 | ProQR Therapeutics | Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation |
FDA applications (0)
This company has no applications containing this asset.